Busca, AlessandroSalmanton-García, JonMarchesi, FrancescoFarina, FrancescaSeval, Guldane CengizDoesum, Jaap A. vanEspigado Tocino, IldefonsoPagano, Livio2025-07-302025-07-302023-02Busca, A., Salmanton-García, J., Marchesi, F., Farina, F., Seval, G.C., Doesum, J.A.v.,...,Pagano, L. (2023). Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Frontiers Immunology, 14. https://doi.org/10.3389/fimmu.2023.1125030.1664-3224https://hdl.handle.net/11441/175819Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.application/pdf9 p.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Allogeneic HSCTCOVID-19 infectionImmunocompromised patientsSARS-CoV-2Hematological malignancesinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.3389/fimmu.2023.1125030